Dechra Pharmaceuticals (LSE:DPH) Cash And Cash Equivalents : £74.4 Mil (As of Jun. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Dechra Pharmaceuticals Cash And Cash Equivalents?

Dechra Pharmaceuticals's quarterly cash and cash equivalents declined from Jun. 2022 (£120.90 Mil) to Dec. 2022 (£87.90 Mil) but then stayed the same from Dec. 2022 (£87.90 Mil) to Jun. 2023 (£74.40 Mil).

Dechra Pharmaceuticals's annual cash and cash equivalents increased from Jun. 2021 (£118.40 Mil) to Jun. 2022 (£120.90 Mil) but then declined from Jun. 2022 (£120.90 Mil) to Jun. 2023 (£74.40 Mil).

Dechra Pharmaceuticals Cash And Cash Equivalents Historical Data

The historical data trend for Dechra Pharmaceuticals's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dechra Pharmaceuticals Cash And Cash Equivalents Chart

Dechra Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Cash And Cash Equivalents

Get a 7-Day Free Trial

80.30

227.40

118.40

120.90

74.40

Dechra Pharmaceuticals Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Cash And Cash Equivalents	Get a 7-Day Free Trial															118.40	123.70	120.90	87.90	74.40

Dechra Pharmaceuticals Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Dechra Pharmaceuticals (LSE:DPH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Dechra Pharmaceuticals Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Dechra Pharmaceuticals's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Dechra Pharmaceuticals (LSE:DPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dechra Pharmaceuticals PLC (LSE:DPH) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

DPHAY:USA DPHl:UK 1PK:Germany

Address

24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich, GBR, CW9 7UA

Website

https://www.dechra.com

Dechra Pharmaceuticals PLC is a major drug manufacturing company with a focus on veterinary pharmaceutical products. The company develops, manufactures, and markets its products exclusively for veterinarians globally. Dechra is structured along three segments, including being European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals Research and Development. The vast majority of Dechra's revenue is generated in Europe, followed by the U.S. Dechra derives most of its revenue through its Companion Animal Product category, followed by food-producing animal products.

Dechra Pharmaceuticals (LSE:DPH) Headlines

No Headlines